secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001628280-26-001774
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition
--------------------------------------------------------------------------------

- Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.
- Updated fluid biomarker data from Phase 1 INTERCEPT-AD study added to presentation.
- ACU234, a new candidate under the EBD program, now listed in pipeline.
- Presentation posted on company website for use in conferences and communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/0001628280-26-001774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/abos-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer